|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Silberman H: Perioperative adjunctive
treatment in the management of operable gastric cancer. J Surg
Oncol. 90(174–186): 186–187. 2005.
|
|
3
|
Arnason T and Harkness T: Development,
Maintenance and Reversal of Multiple Drug Resistance: At the
Crossroads of TFPI1, ABC Transporters and HIF1. Cancers (Basel).
7:2063–2082. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dehghanzadeh R, Jadidi-Niaragh F, Gharibi
T and Yousefi M: MicroRNA-induced drug resistance in gastric
cancer. Biomed Pharmacother. 74:191–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gong J, Cui Z, Li L, Ma Q, Wang Q, Gao Y
and Sun H: MicroRNA-25 promotes gastric cancer proliferation,
invasion and migration by directly targeting F-box and WD-40 Domain
Protein 7, FBXW7. Tumour Biol. 36:7831–7840. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang M, Wang X, Li W and Cui Y: miR-107
and miR-25 simultaneously target LATS2 and regulate proliferation
and invasion of gastric adenocarcinoma (GAC) cells. Biochem Biophys
Res Commun. 460:806–812. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao H, Wang Y, Yang L, Jiang R and Li W:
MiR-25 promotes gastric cancer cells growth and motility by
targeting RECK. Mol Cell Biochem. 385:207–213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li BS, Zuo QF, Zhao YL, Xiao B, Zhuang Y,
Mao XH, Wu C, Yang SM, Zeng H, Zou QM and Guo G: MicroRNA-25
promotes gastric cancer migration, invasion and proliferation by
directly targeting transducer of ERBB2, 1 and correlates with poor
survival. Oncogene. 34:2556–2565. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu X, Zhang Y, Liu Z, Zhang X and Jia J:
miRNA-532-5p functions as an oncogenic microRNA in human gastric
cancer by directly targeting RUNX3. J Cell Mol Med. 20:95–103.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu W, An J, Li K and Hou H: MiR-429
regulates gastric cancer cell invasiveness through ZEB proteins.
Tumour Biol. 2015.(Epub ahead of print).
|
|
14
|
Nho RS and Hergert P: FoxO3a and disease
progression. World J Biol Chem. 5:346–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang H and Tindall DJ: FOXO factors: A
matter of life and death. Future Oncol. 2:83–89. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dijkers PF, Medema RH, Pals C, Banerji L,
Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW,
Koenderman L and Coffer PJ: Forkhead transcription factor FKHR-L1
modulates cytokine-dependent transcriptional regulation of p27
(KIP1). Mol Cell Biol. 20:9138–9148. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rathbone CR, Booth FW and Lees SJ: FoxO3a
preferentially induces p27Kip1 expression while
impairing muscle precursor cell-cycle progression. Muscle Nerve.
37:84–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ray A, James MK, Larochelle S, Fisher RP
and Blain SW: p27Kip1 inhibits cyclin D-cyclin-dependent
kinase 4 by two independent modes. Mol Cell Biol. 29:986–999. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Borriello A, Cucciolla V, Oliva A, Zappia
V and Ragione F Della: p27Kip1 metabolism: A fascinating
labyrinth. Cell cycle. 6:1053–1061. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park SH, Jang KY, Kim MJ, Yoon S, Jo Y,
Kwon SM, Kim KM, Kwon KS, Kim CY and Woo HG: Tumor suppressive
effect of PARP1 and FOXO3A in gastric cancers and its clinical
implications. Oncotarget. 6:44819–44831. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu S, Yu Y, Sun Y, Wang X, Luo R, Zhao N,
Zhang W, Li Q, Cui Y, Wang Y, et al: Activation of FOXO3a suggests
good prognosis of patients with radically resected gastric cancer.
Int J Clin Exp Pathol. 8:2963–2970. 2015.PubMed/NCBI
|
